Immuno-Oncology in vitro Assays  

Perform initital screening tests using InnoSer’s in vitro immuno-oncology assays to select your lead candidate compounds and progress to in vivo studies with confidence   

Home » Oncology CRO Services » Immuno-Oncology in vitro Assays  

Immuno-oncology in vitro assays are carried out using cancer-associated rodent (murine, rat) or human immortalized cell lines, representing a powerful tool to perform high throughput drug screening studies. Accordingly, InnoSer offers a selection of commercially available cancer cell lines ideal for progressing your compound from a hit to a lead candidate.  

Assays using rodent or human cell lines are efficient, relatively inexpensive, and easy to set up (study duration 1-2 weeks). Therefore, providing you with a wealth of information on your compound efficacy, and mechanisms of action. However, to capture patient and tumor heterogeneity early on in your initial in vitro screening studies, InnoSer recommends working with patient-derived organoids (tumoroids). Accordingly, in vitro assays can be used before or in conjunction with running your in vivo studies in InnoSer’s syngeneic mouse models or cell line-derived xenograft (CDX) mouse models.

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions in the most cost-effective way. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio. 

Services with immuno-oncology in vitro assays that InnoSer offers:  

  • Cancer-associated tumor and microenvironment-associated cell lines (human and rodent).
  • Co-cultures (human and rodent) and 3D cell cultures (tumoroids). 

Find the right model for you.

Compare our model capabilities and discover which of our oncology platforms suits your research needs

oncology leaflet download

Key immuno-oncology in vitro assays:

Test the efficacy of your treatments with the following immuno-oncology in vitro assays: 

  • Live cell imaging (proliferation, apoptosis, phagocytosis, cell motility)  
  • Proliferation (BrdU quantification, cell viability, metabolic activity)  
  • Migration assay (Scratch assay, Boyden chamber analysis)  
  • Invasion assay (spheroids assay, measurement of EMT features) 
  • Apoptosis (Annexin V-PI, caspases) 
  • Cell cycle analysis  
  • Invasion  
  • Angiogenesis assay 
  • Cytokine release assessment  
  • Quantitative biomarker analysis (MSD, ELISA)  
  • Gene expression and protein expression analyses  
  • High-content imaging (3D imaging, confocal microscopy)  
  • Immunoassays (ELISA)  
  • Biomarker analyses, cytotoxicity, cell migration, and proliferation assays 

Related model options

Oncology Platform Overview

Highly relevant oncology CRO services to facilitate preclinical drug development.

Patient-derived organoids (tumoroids)

Access InnoSer’s high-throughput drug screening capabilities. 

Syngeneic Mouse Models

InnoSer offers contract research services using subcutaneous and orthotopic syngeneic mouse models.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

AAALAC logo

Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know